News Related to ES-SCLC

Related coverage linked through entity extraction aliases.

GSK's Risvutatug Rezetecan Receives Orphan Drug Designation in Japan for Small-Cell Lung Cancer

Mar 23, 2026

GSK's antibody-drug conjugate risvutatug rezetecan has received Orphan Drug Designation in Japan for small-cell lung cancer, marking its sixth global regulatory designation. The decision was based on phase I trial data showing durable responses in extensive-stage SCLC patients. The drug is currently in phase III development for relapsed ES-SCLC.

CStone's CS2009 Trispecific Antibody Receives FDA Clearance for Phase II Trial

Feb 16, 2026

CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.

CStone Pharmaceuticals Receives FDA Clearance for CS2009 Phase II Trial in Advanced Solid Tumors

Feb 16, 2026

CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.